new_0222_0359|PRLD|Short Name|0|0|total_current_assets|cash_on_hand|inventories_net|net_ppe|goodwill_and_intangible|liabilities|total_current_liabilities|total_long_term_liab|total_deposits|book_value_of_equity|retained_earnings|treasury_stock|ev_revenues|ev_earnings|ev_free_cash_flow|ev_assets|ps_ratio|pe_ratio|price_to_book_value|peg_ratio|debt_equity_ratio|dividend_yield|shareholder_yield_ttm|percent_of_shares_outstanding|receivables|payables|capital_stock|return_on_invested_capital|quality_ratio_fractile|momentum_fractile|market_beta_12_month|sustainable_growth_rate|institutional_investor_ownership_percentage|average_shares_outs_diluted|total_employee_number|eps|sga_expense|shares_outstanding|repurchase_of_capital_stock|ordinary_shares_number|payout_ratio|quick_ratio|normalized_eps|stock_buyback|effective_tax_rate|return_on_equity|net_income_ttm|revenues_ttm|dividend_per_share|revenues|gross_profit|pre_tax_income|net_income|interest_income|price|total_return_price|enterprise_value|average_volume_30|one_year_return|short_interest|forward_pe_ratio|forward_pe_ratio_1y|forward_ps_ratio|forward_ps_ratio_1y|quarterly_eps_estimates|quarterly_sales_estimates|quarterly_eps_surprise|quarterly_sales_surprise|quarterly_eps_actual|quarterly_sales_actual|sales_est_0y|sales_est_1y|price_target|consensus_recommendation|price_target_num_est|eps_est_0y|eps_est_1y|r_and_d_expense|reconciled_depreciation|interest_expense_non_operating|land_and_improvements|buildings_and_improvements|other_properties|machinery_furniture_equipment
new_0222_0359|PRLD|Long Name|1|1|Prelude Therapeutics Inc Total Current Assets (Quarterly) (USD)|Prelude Therapeutics Inc Cash and Short Term Investments (Quarterly) (USD)|Prelude Therapeutics Inc Inventories (Quarterly) (USD)|Prelude Therapeutics Inc Net PP&E (Quarterly) (USD)|Prelude Therapeutics Inc Goodwill and Intangibles (Quarterly) (USD)|Prelude Therapeutics Inc Total Liabilities (Quarterly) (USD)|Prelude Therapeutics Inc Total Current Liabilities (Quarterly) (USD)|Prelude Therapeutics Inc Total Long Term Liabilities (Quarterly) (USD)|Prelude Therapeutics Inc Total Deposits (Quarterly) (USD)|Prelude Therapeutics Inc Book Value (Quarterly) (USD)|Prelude Therapeutics Inc Retained Earnings (Quarterly) (USD)|Prelude Therapeutics Inc Treasury Stock (Quarterly) (USD)|Prelude Therapeutics Inc EV to Revenues|Prelude Therapeutics Inc EV to Earnings|Prelude Therapeutics Inc EV to Free Cash Flow|Prelude Therapeutics Inc EV to Assets (Quarterly)|Prelude Therapeutics Inc PS Ratio|Prelude Therapeutics Inc PE Ratio|Prelude Therapeutics Inc Price to Book Value|Prelude Therapeutics Inc PEG Ratio|Prelude Therapeutics Inc Debt to Equity Ratio|Prelude Therapeutics Inc Dividend Yield|Prelude Therapeutics Inc Shareholder Yield (TTM)|Prelude Therapeutics Inc Percent of Shares Outstanding Short|Prelude Therapeutics Inc Total Receivables (Quarterly) (USD)|Prelude Therapeutics Inc Total Payables (Quarterly) (USD)|Prelude Therapeutics Inc Total Capital Stock (Quarterly) (USD)|Prelude Therapeutics Inc Return on Invested Capital|Prelude Therapeutics Inc Quality Ratio Score|Prelude Therapeutics Inc Momentum Score|Prelude Therapeutics Inc Beta (1Y)|Prelude Therapeutics Inc Sustainable Growth Rate (TTM)|Prelude Therapeutics Inc Institutional Investor Ownership Percentage|Prelude Therapeutics Inc Average Diluted Shares Outstanding (Quarterly)|Prelude Therapeutics Inc Total Employees (Annual)|Prelude Therapeutics Inc EPS Diluted (Quarterly) (USD)|Prelude Therapeutics Inc SG&A Expense (Quarterly) (USD)|Prelude Therapeutics Inc Shares Outstanding|Prelude Therapeutics Inc Repurchase of Capital Stock (Quarterly) (USD)|Prelude Therapeutics Inc Ordinary Shares Number (Quarterly)|Prelude Therapeutics Inc Payout Ratio|Prelude Therapeutics Inc Quick Ratio (Quarterly)|Prelude Therapeutics Inc Normalized Diluted EPS (Quarterly) (USD)|Prelude Therapeutics Inc Stock Buybacks (Quarterly) (USD)|Prelude Therapeutics Inc Effective Tax Rate (TTM)|Prelude Therapeutics Inc Return on Equity|Prelude Therapeutics Inc Net Income (TTM) (USD)|Prelude Therapeutics Inc Revenue (TTM) (USD)|Prelude Therapeutics Inc Dividend Per Share (Quarterly) (USD)|Prelude Therapeutics Inc Revenue (Quarterly) (USD)|Prelude Therapeutics Inc Gross Profit (Quarterly) (USD)|Prelude Therapeutics Inc Pre-Tax Income (Quarterly) (USD)|Prelude Therapeutics Inc Net Income (Quarterly) (USD)|Prelude Therapeutics Inc Net Interest Income (Quarterly) (USD)|Prelude Therapeutics Inc Price (USD)|Prelude Therapeutics Inc Total Return Price (USD)|Prelude Therapeutics Inc Enterprise Value (USD)|Prelude Therapeutics Inc 30-Day Average Daily Volume|Prelude Therapeutics Inc 1 Year Price Returns (Daily)|Prelude Therapeutics Inc Short Interest|Prelude Therapeutics Inc PE Ratio (Forward)|Prelude Therapeutics Inc PE Ratio (Forward 1y)|Prelude Therapeutics Inc PS Ratio (Forward)|Prelude Therapeutics Inc PS Ratio (Forward 1y)|Prelude Therapeutics Inc Quarterly EPS Estimates (USD)|Prelude Therapeutics Inc Quarterly Revenue Estimates (USD)|Prelude Therapeutics Inc Quarterly EPS Surprise|Prelude Therapeutics Inc Quarterly Revenue Surprise|Prelude Therapeutics Inc Quarterly Actual EPS (USD)|Prelude Therapeutics Inc Quarterly Actual Revenue (USD)|Prelude Therapeutics Inc Revenue Estimates for Current Fiscal Year (USD)|Prelude Therapeutics Inc Revenue Estimates for Next Fiscal Year (USD)|Prelude Therapeutics Inc Price Target (USD)|Prelude Therapeutics Inc Consensus Recommendation|Prelude Therapeutics Inc Price Target Num Estimates|Prelude Therapeutics Inc EPS Estimates for Current Fiscal Year (USD)|Prelude Therapeutics Inc EPS Estimates for Next Fiscal Year (USD)|Prelude Therapeutics Inc Research and Development Expense (Quarterly) (USD)|Prelude Therapeutics Inc Reconciled Depreciation (Quarterly) (USD)|Prelude Therapeutics Inc Non-Operating Interest Expense (Quarterly) (USD)|Prelude Therapeutics Inc Land and Improvements (Quarterly) (USD)|Prelude Therapeutics Inc Buildings and Improvements (Quarterly) (USD)|Prelude Therapeutics Inc Other Properties (Quarterly) (USD)|Prelude Therapeutics Inc Machine, Furniture & Equipment (Quarterly) (USD)
new_0222_0359|PRLD|Unit|2|2|mil_figure_money_USD_metric|mil_figure_money_USD_metric|mil_figure_money_USD_metric|mil_figure_money_USD_metric|mil_figure_money_USD_metric|mil_figure_money_USD_metric|mil_figure_money_USD_metric|mil_figure_money_USD_metric|mil_figure_money_USD_metric|mil_figure_money_USD_metric|mil_figure_money_USD_metric|mil_figure_money_USD_metric|figure_USD_metric|figure_USD_metric|figure_USD_metric|figure_USD_metric|figure_USD_metric|figure_USD_metric|figure_USD_metric|figure_USD_metric|figure_USD_metric|percent_USD_metric|percent_USD_metric|percent_USD_metric|mil_figure_money_USD_metric|mil_figure_money_USD_metric|mil_figure_money_USD_metric|percent_USD_metric|figure_USD_metric|figure_USD_metric|figure_USD_beta|percent_USD_metric|percent_USD_metric|mil_figure_USD_metric|figure_whole_USD_metric|figure_money_USD_per_share_metric|mil_figure_money_USD_metric|mil_figure_USD_metric|mil_figure_money_USD_metric|mil_figure_USD_metric|percent_USD_metric|figure_USD_metric|figure_money_USD_per_share_metric|mil_figure_money_USD_metric|percent_USD_metric|percent_USD_metric|mil_figure_money_USD_metric|mil_figure_money_USD_metric|figure_money_USD_per_share_metric|mil_figure_money_USD_metric|mil_figure_money_USD_metric|mil_figure_money_USD_metric|mil_figure_money_USD_metric|mil_figure_money_USD_metric|figure_money_USD_price|figure_money_USD_price|mil_figure_money_USD_metric|figure_USD_metric|percent_USD_metric|figure_USD_metric|figure_USD_metric|figure_USD_metric|figure_USD_metric|figure_USD_metric|figure_money_USD_per_share_metric|mil_figure_money_USD_metric|percent_USD_per_share_metric|percent_USD_metric|figure_money_USD_per_share_metric|mil_figure_money_USD_metric|mil_figure_money_USD_metric|mil_figure_money_USD_metric|figure_money_USD_price|figure_USD_metric|figure_whole_USD_price|figure_money_USD_per_share_metric|figure_money_USD_per_share_metric|mil_figure_money_USD_metric|mil_figure_money_USD_metric|mil_figure_money_USD_metric|mil_figure_money_USD_metric|mil_figure_money_USD_metric|mil_figure_money_USD_metric|mil_figure_money_USD_metric
new_0222_0359|PRLD||4|4|quarterly|quarterly|quarterly|quarterly|quarterly|quarterly|quarterly|quarterly|quarterly|quarterly|quarterly|quarterly|quarterly|quarterly|daily|quarterly|quarterly|quarterly|daily|quarterly|quarterly|daily|quarterly|monthly|quarterly|quarterly|quarterly|quarterly|quarterly|monthly|monthly|quarterly|quarterly|quarterly|quarterly|quarterly|quarterly|monthly|quarterly|quarterly|quarterly|quarterly|quarterly|quarterly|quarterly|quarterly|quarterly|quarterly|quarterly|quarterly|quarterly|quarterly|quarterly|quarterly|daily|daily|daily|daily|daily|monthly|quarterly|quarterly|quarterly|quarterly|quarterly|quarterly|quarterly|quarterly|quarterly|quarterly|quarterly|quarterly|monthly|monthly|monthly|monthly|monthly|quarterly|quarterly|quarterly|quarterly|quarterly|quarterly|quarterly
new_0222_0359|PRLD||5|5|106.5|106.5|0|106.5|0|106.5|106.5|106.5|0|106.5|106.5|0|0|0|1.44755244755|0|0|0|1.44571428571|0|0|1.44759206799|0|15.25|0|106.5|106.5|0|0|30.6666666667|30.75|0|0|91.375|91.4|91.375|91.375|25.5625|0|106.5|0|0|91.375|91.3333333333|0|0|91.4|0|0|0|0|91.375|91.375|0|1.44759206799|1.44759206799|1.44759206799|1.45061728395|1.42574257426|15.25|0|0|0|0|91.3333333333|91.4285714286|91.25|0|91.25|91.5|50.75|101.5|18.72|16.1379310345|18.72|18|22.2857142857|91.375|91.375|0|0|0|106.5|122
new_0222_0359|PRLD||6|6|6|6|0|6|0|6|6|6|0|6|6|0|0|0|286|0|0|0|350|0|0|353|0|32|0|6|6|0|0|3|4|0|0|8|5|8|8|16|0|6|0|0|8|6|0|0|5|0|0|0|0|8|8|0|353|353|353|324|101|32|0|0|0|0|9|7|4|0|4|2|4|2|25|29|25|26|21|8|8|0|0|0|6|3
new_0222_0359|PRLD||7|7|quarterly|quarterly|quarterly|quarterly|quarterly|quarterly|quarterly|quarterly|quarterly|quarterly|quarterly|quarterly|daily|quarterly|daily|quarterly|daily|daily|daily|daily|quarterly|daily|quarterly|daily|quarterly|quarterly|quarterly|quarterly|quarterly|monthly|monthly|quarterly|monthly|quarterly|yearly|quarterly|quarterly|daily|quarterly|quarterly|quarterly|quarterly|quarterly|quarterly|quarterly|quarterly|quarterly|quarterly|quarterly|quarterly|quarterly|quarterly|quarterly|quarterly|market_daily|market_daily|daily|market_daily|market_daily|daily|daily|daily|daily|daily|quarterly|quarterly|quarterly|quarterly|quarterly|quarterly|daily|daily|daily|daily|daily|daily|daily|quarterly|quarterly|quarterly|quarterly|quarterly|quarterly|quarterly
new_0222_0359|PRLD|201909|201909|201909||||||||||||||||||||||||||||||||||32.4018||-0.2078|1.394||||||-0.2078|||||||||-6.734|-6.734|||||||||||||||||||||||||5.49|0.099|||||
new_0222_0359|PRLD|201912|201912|201912|20.224|18.879||1.647||71.283|4.835|66.448||-49.412|-50.497|||||||||||||||1.974|0|||||||32.4018||-0.3098|1.246|||42.4546|||-0.3098|||||||||-10.039|-10.039|||||||||||||||||||||||||8.849|0.128||||1.842|0.049
new_0222_0359|PRLD|202003|202003|202003||||||||||||||||||||||||||||||||||32.4018||-0.2935|1.201||||||-0.2935|0||||||||-9.511|-9.511|||||||||||||||||||||||||8.536|0.132|||||
new_0222_0359|PRLD|202006|202006|202006|30.697|29.716||1.575||102.058|5.639|96.419||-69.311|-71.416|||||||||||||||3.471|0|||||||42.4546|51|-0.2687|1.66|||42.4546|||-0.2687|0|||-37.692|||||-11.408|-11.408|||||||||||||||||||||||||9.776|0.135|||||
new_0222_0359|PRLD|202009|202009|202009|238.061|234.792||1.62||11.374|11.359|0.015||228.307|-88.176||||||||5.7676|||0||0.0132||5.074|0.004|||||||3.1945|55|-5.25|2.851|43.7034||43.7034|||-5.25|-167.929|||-47.718|||||-16.76|-16.76||30.13|30.13|1081.9914|||5757|||||-0.345||-11.1565||-0.3835|||||||||15.293|0.142|||||
new_0222_0359|PRLD|202010|202009|202009|||||||||||||||||||6.7439|||0||0.7318|||||||||||||||||||||||||||||||35.23|35.23|1304.8788|||319808|||||||||||||35.5|3|2|-1.77|-1.8767|||||||
new_0222_0359|PRLD|202011|202009|202009|||||||||||||||||||9.8526|||0||1.212|||||||||85.9318|||||43.7034|||||||||||||||||51.47|51.47|2014.622|117394.5333||529676|||||||||||||45|3|3|-3.5167|-2.01|||||||
new_0222_0359|PRLD|202012|202012|202012|220.809|218.309||2.48||11.407|11.375|0.032||212.183|-107.426||||-62.1572||||14.738|||0||2.8086||3.92|0.004|||||||43.7057|68|-0.4404|4.874|43.7057||43.7057|||-0.4404|1.299|||-56.929|||||-19.25|-19.25||71.55|71.55|2908.8338|195008.9667||1227525|||||-0.4933||10.719||-0.4405||||48|3|3|-3.4933|-2.0767|14.572|0.133||||3.01|0.105
new_0222_0359|PRLD|202101|202012|202012|||||||||||||||-59.9803||||14.2578|||0||3.1494||||||||||||||46.5784|||||||||||||||||64.95|64.95|2806.9581|317060.4||1466943|||||||||||||48|3|3|-2.0767||||||||
new_0222_0359|PRLD|202102|202012|202012|||||||||||||||-57.3726||||13.6827|||0||3.0515|||||||||||||||||||||||||||||||62.33|62.33|2684.9227|160864.1333||1421336||||||||||||||||||||||||
new_0222_0359|PRLD|202103|202103|202103|365.018|362.99||4.813||13.264|12.424|0.84||356.567|-128.726||||-30.8656||||5.686|||0||3.6742||4.842|0.005|||||||45.122|105|-0.47|5.497|46.7909||46.7909|||-0.47|-161.424|||-68.718|||||-21.3|-21.3||43.33|43.33|1664.4597|200349.4333||1719180|||||-0.424|0|-10.8491||-0.47|0|||62.5|2.75|4|-1.87|-2.805|16.47|0.16||||4.813|
new_0222_0359|PRLD|202104|202103|202103|||||||||||||||-29.3071||||5.4503|||0||4.1279||||||||||||||46.8968|||||||||||||||||41.44|41.44|1580.4134|285619.6667||1935845|||||||||||0|0|62.4|2.6|5|-1.894|-2.954|||||||
new_0222_0359|PRLD|202105|202103|202103|||||||||||||||-23.5374||||4.5777|||0||4.3691||||||||||||||46.9582|||||||||||||||||34.76|34.76|1269.277|214130.8667||2051666|||||||||||0||62|2.6|5|-2.09|-3.096|||||||
new_0222_0359|PRLD|202106|202106|202106|344.575|343.119||5.006||15.22|14.677|0.543||334.361|-155.591||||-15.3749||||4.0277|||0||7.231||6.844|0.005|||||||46.0571|100|-0.58|5.513|47.0387||47.0387|||-0.58|0|||-84.175|||||-26.865|-26.865||28.63|28.63|1003.599|224939.7||3401355|||||-0.494|0|-17.4089||-0.58|0||||||||22.409|0.199||||5.006|
new_0222_0359|PRLD|202107|202106|202106|||||||||||||||-17.8323||||4.5075|||0||8.7773|||||||||||||||||||||||||||||||32.04|32.04|1164.0009|216628.9667||4128749|||||||||||||62|2.2|5|||||||||
new_0222_0359|PRLD|202108|202106|202106|||||||||||||||-20.4925||||5.0268|||0||8.7618||||||||||||||47.0935|||||||||||||||||35.69|35.69|1337.648|178832.8667||4126262|||||||||||0||61.6|2.2|5|-2.346|-3.282|||||||
new_0222_0359|PRLD|202109|202109|202109|325.897|320.865||5.32||19.975|19.663|0.312||311.242|-186.278||||-15.3787||||4.7383|||0||9.4094||11.062|0.005||||2.5212|||46.3308|113|-0.66|8.115|47.1918||47.1918|||-0.66|0|||-98.102|||||-30.687|-30.687||31.25|31.25|1153.8788|354084.1|3.7172|4440453|||||-0.625|0|-5.6||-0.66|0||||||||22.721|0.266||||5.32|
new_0222_0359|PRLD|202110|202109|202109|||||||||||||||-6.7808||||2.6656|||0||10.587||||||4|2.0799||||||||||||||||||||||||17.58|17.58|508.7668|745763.1667|-49.4537|4996211|||||||||||0|0|47.5|1.75|4|-2.345|-3.295|||||||
new_0222_0359|PRLD|202111|202109|202109|||||||||||||||-4.716||||2.1678|||0||11.4933||||||1|-0.3083|||||||47.2154|||||||||||||||||14.29|14.29|353.8431|334619.8|-72.2363|5426579|||||||||||0|0|42.25|1.75|4|-2.4025|-3.3675|||||||
new_0222_0359|PRLD|202112|202112|202112|||||||||||||||-3.5581||||1.8887|||0||10.8962||||||1|-1.1063||||||||||||||||||||||||12.45|12.45|266.9667|468497.9333|-82.5996|5144659|||||-0.6825|0|||||||41.75|1.75|4|-2.4025|-3.365|||||||
new_0222_0359|PRLD|202201|202112|202112|||||||||||||||-1.9723||||1.5064|||0||9.4872||||||1|-0.3823||||||||||||||||||||||||9.93|9.93|147.9839|449422.9333|-84.7113|4479414|||||||||||||38|1.75|4|-3.375|-2.75|||||||
new_0222_0359|PRLD|202202|202112|202112|||||||||||||||-2.0352||||1.5216|||0|||||||||||||||||||||||||||||||||10.03|10.03|152.7055|266824.0667|-86.8494|||||||||||||||||||||||||
new_0222_0359|PRLD|202203|202203|202203|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||-0.69|0||||||||||||||||||
new_0222_0359|PRLD|202206|202206|202206|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||-0.735|0||||||||||||||||||
new_0222_0359|PRLD|202209|202209|202209|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||-0.77|0||||||||||||||||||
new_0222_0359|PRLD|202212|202212|202212|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||-0.81|0||||||||||||||||||